

## Unverdorben, Martin

---

**From:** Kimberly Prchal [Kimberly.Prchal@mdsps.com]  
**Sent:** Thursday, February 06, 2003 4:02 PM  
**To:** Hans-Juergen.Roethig@pmusa.com; martin.unverdorben@pmusa.com;  
Mohamadi.Sarkar@pmusa.com; Jan.Oey@pmusa.com; Bettie.L.Nelson@pmusa.com;  
valerie.a.king@pmusa.com; paul.mendes@pmusa.com; robin.d.kinser@pmusa.com  
**Cc:** Michael Szwaneke; Megan Mccrory; Chad Briscoe; Peggy Ruhn; Mary Hetrick  
**Subject:** Admin Changes for Montreal Transfers  
**Sensitivity:** Confidential

All,

The decision has been made to transfer methods for 1-OHP, 3-HPMA, SPMA and 1,3-But Metabolites to Montreal for analysis. Currently, all of the protocols state that the samples are to be shipped to LNK. We need to do an Administrative Change for all of the current protocols, changing shipping from LNK to Montreal.

Mike will start on these soon and send to the next available IRB meeting for review.

Studies effected:  
ECHJLI/02/02 (28123)  
SCoR2003-6/02/02 (AA01564)  
SCoR2003-11/01/03 (AA02243)  
SCoR2003-11/02/03 (AA02980)

Mike will also add the shipping to Montreal to the Final ECHJLI Short Term Menthol study (AA04271) and the Series K studies.

Thanks  
Kim

Kimberly M. Prchal  
Senior Project Manager  
MDS Pharma Services - Lincoln, NE  
kimberly.prchal@mdsps.com  
402.437.4773